Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

PTAB Finds Chugai/Roche’s Actemra® (Tocilizumab) Patents Invalid Following Celltrion’s IPRs

Aug 29, 2023

The Patent Trial and Appeal Board (PTAB) issued decisions in Celltrion’s two inter partes reviews (IPRs) (IPR2022-00578 and IPR2022-00579), finding Chugai and Roche’s tocilizumab patents (US patent nos. 8,580,264 and 10,874,677) were invalid.  The PTAB found that claims 1-12 of the ‘264 patent were anticipated and/or obvious, and claims 1-8 of the ‘677 patent were obvious.

The PTAB instituted Celltrion’s two IPRs of Chugai and Roche’s tocilizumab patents on 31 August 2022.